<DOC>
	<DOCNO>NCT00547339</DOCNO>
	<brief_summary>RATIONALE : Stereotactic body radiation therapy may able send x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase I/II trial study side effect best dose stereotactic body radiation therapy see well work treat patient prostate cancer .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To escalate dose stereotactic body radiotherapy ( SBRT ) tumoricidal dose without exceed maximum tolerate dose patient organ-confined prostate cancer . ( Phase I ) - To determine late , severe grade 3-5 genitourinary gastrointestinal toxicity occur 270-540 day ( i.e. , 9-18 month ) start protocol treatment assess CTCAE v3.0 . ( Phase II ) Secondary - To determine dose-limiting toxicity SBRT patient . ( Phase I ) - To determine 2-year biochemical ( PSA ) control ( freedom PSA failure ) , disease-free overall survival , local control , freedom distant metastasis , incidence high-grade adverse event type patient treat therapy order determine therapy promise enough clinical investigation . ( Phase II ) OUTLINE : This multicenter , phase I dose-escalation study follow phase II open-label study . - Phase I : Patients undergo 5 treatment stereotactic body radiotherapy ( SBRT ) . - Phase II : Patients undergo SBRT maximum tolerate dose phase I . After completion study treatment , patient follow 1.5 , 3 , 6 , 9 , 12 month , every 6 month 5 year , year year 5-10 . PROJECTED ACCRUAL : A total 97 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Stage T1a , T1b , T1c disease Stage T2a T2b No direct evidence regional distant metastases No T2c , T3 , T4 tumor Gleason score ≤ 7 Must meet follow criterion : Prostatespecific antigen ( PSA ) ≤ 20 ng/mL prior start hormonal therapy ( give ) patient Gleason score 26 PSA ≤ 15 ng/mL prior start hormonal therapy ( give ) patient Gleason score 7 Risk pelvic lymph node involvement &lt; 20 % accord Roach formula Ultrasoundbased volume estimation prostate gland ≤ 60 g PATIENT CHARACTERISTICS : Zubrod performance status 02 Fertile patient must use effective contraception No prior invasive malignancy , except nonmelanoma skin cancer , unless diseasefree minimum 3 year ( e.g. , carcinoma situ breast , oral cavity , cervix allow ) No significant urinary obstructive symptom American Urological Association ( AUA ) score ≤ 15 ( alpha blocker allow ) No history inflammatory colitis ( include Crohn disease ulcerative colitis ) No history significant psychiatric illness No severe , active comorbidity include follow : Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day prior registration Hepatic insufficiency result clinical jaundice and/or coagulation defect Laboratory test liver function coagulation parameter require entry protocol AIDS ( base current CDC definition ) immunocompromising condition HIV testing require entry protocol PRIOR CONCURRENT THERAPY : See Disease Characteristics More 9 month since prior hormonal therapy neoadjuvant therapy downsize prostate gland No prior pelvic radiotherapy No prior chemotherapy surgery prostate cancer No prior transurethral resection prostate ( TURP ) cryotherapy prostate No plan concurrent posttreatment , adjuvant , antineoplastic therapy include surgery , cryotherapy , conventionally fractionate radiotherapy , hormonal therapy , chemotherapy part treatment prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>